WallStSmart

Dynavax Technologies Corporation (DVAX)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 19799% more annual revenue ($65.77B vs $330.51M). MRK leads profitability with a 13.6% profit margin vs -0.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).

DVAX

Hold

45

out of 100

Grade: D+

Growth: 3.3Profit: 3.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.98

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DVAX.

MRKOvervalued (-13.8%)

Margin of Safety

-13.8%

Fair Value

$97.84

Current Price

$111.38

$13.54 premium

UndervaluedFair: $97.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVAX0 strengths · Avg: 0/10

No standout strengths identified

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

DVAX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

EPS GrowthGrowth
0.7%4/10

0.7% earnings growth

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.2%3/10

Operating margin of 0.2%

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : DVAX

DVAX has a balanced fundamental profile.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : DVAX

The primary concerns for DVAX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

DVAX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

DVAX carries more volatility with a beta of 0.93 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dynavax Technologies Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?